A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Infigratinib (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=21) assessing tumor tissue response at a single center presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 23 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top